high-intensity ultrasound

FDA panel rejects high intensity focused ultrasound for early prostate cancer

Charlie Schmidt

Editor, Harvard Medical School Annual Report on Prostate Diseases

An FDA advisory panel rejected a French company’s application to market high intensity focused ultrasound as a treatment for localized prostate cancer.